Ken Stern & Associates Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 7.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,906 shares of the biopharmaceutical company’s stock after purchasing an additional 1,266 shares during the quarter. Ken Stern & Associates Inc.’s holdings in Pfizer were worth $686,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of PFE. Naples Global Advisors LLC boosted its stake in shares of Pfizer by 5.4% in the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after buying an additional 1,712 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in Pfizer by 25.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock worth $10,352,000 after purchasing an additional 57,176 shares during the last quarter. Destination Wealth Management lifted its stake in Pfizer by 962,667.3% during the second quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock worth $18,163,000 after purchasing an additional 500,587 shares during the last quarter. Gagnon Securities LLC lifted its stake in Pfizer by 61.1% during the first quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,581 shares during the last quarter. Finally, Pennsylvania Trust Co lifted its stake in Pfizer by 10.9% during the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock worth $28,127,000 after purchasing an additional 67,151 shares during the last quarter. 69.01% of the stock is currently owned by institutional investors.
Several research firms have weighed in on PFE. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Morningstar set a $46.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 9th. Independent Research set a $48.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Barclays set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Friday, October 19th. Finally, Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $42.95.
In other news, major shareholder Pfizer Inc purchased 55,556 shares of the company’s stock in a transaction dated Monday, October 15th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the completion of the transaction, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by corporate insiders.
Shares of PFE opened at $43.67 on Friday. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $45.81. The firm has a market capitalization of $255.32 billion, a PE ratio of 16.48, a PEG ratio of 2.19 and a beta of 0.96. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.34% and a net margin of 44.63%. The company had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. During the same period in the prior year, the company earned $0.67 EPS. Pfizer’s revenue was up 1.0% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 3 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s payout ratio is 51.32%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Recommended Story: Intrinsic Value
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.